Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Now Rated “Hold” by Wall Street Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average rating of “Hold” by the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.20.

XERS has been the topic of a number of research analyst reports. Leerink Partners upped their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Barclays boosted their price objective on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00. Following the completion of the sale, the insider directly owned 1,351,053 shares in the company, valued at $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00. Following the sale, the insider owned 1,599,208 shares of the company’s stock, valued at approximately $15,048,547.28. The trade was a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 134,998 shares of company stock valued at $1,202,666 over the last three months. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently made changes to their positions in the stock. Allworth Financial LP grew its position in Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after acquiring an additional 2,000 shares in the last quarter. AlphaCentric Advisors LLC increased its stake in Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after acquiring an additional 2,494 shares during the last quarter. GK Wealth Management LLC purchased a new stake in Xeris Biopharma during the third quarter valued at about $32,000. KBC Group NV purchased a new stake in Xeris Biopharma during the first quarter valued at about $27,000. Finally, Royal Bank of Canada raised its position in Xeris Biopharma by 12.9% during the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock valued at $253,000 after purchasing an additional 4,974 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Stock Up 0.7%

XERS opened at $10.86 on Friday. The company has a fifty day moving average price of $9.09 and a 200-day moving average price of $7.79. The firm has a market capitalization of $1.98 billion, a P/E ratio of -98.73 and a beta of 0.53. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma has a one year low of $5.25 and a one year high of $11.41.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Equities research analysts expect that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.